Artificial intelligence (AI) is currently revolutionizing the healthcare system, where AI-based software is increasingly becoming a part of medical procedures: Robots are providing assistance during operations, while wearables are measuring every pulse beat and are transmitting the data to doctors. Moreover, researchers are developing AI that can recognize cardiovascular and blood diseases. Already today, visual scans are used for remote medical screenings.
This development is also opening up great opportunities for pharmaceutical and biotech manufacturers, because AI is useful not only for smart medical solutions but also for the pharmaceutical development and production. In the future, software solutions that include AI are expected to help discover and exploit optimization potential that is hidden today, thus maximizing the yield of a pharmaceutical product or reducing production costs, for example.
Making AI usable for pharma and biotech industries: As pharmaceutical and biotech companies optimize processes, they constantly strive to increase the output of a product while boosting their quality and reducing the share of error-prone manual processes at the same time. Here, AI will play a key role.
However, for manufacturing purposes only validated software systems may be used in regulated industries such as pharma and biotech. This means that any piece of software applied in this process needs to be tested to fulfill a strict set of predefined rules regarding its reliability and reproducibility. Such rules have not yet been fully established for AI systems, because their results are always subject to a certain degree of probability.